Singapore markets open in 7 hours 37 minutes
Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,027.99 -43.64 (-0.86%) Dow
37,988.19 -472.73 (-1.23%) Nasdaq
15,527.61 -185.14 (-1.18%) Bitcoin USD
64,504.73 -386.72 (-0.60%) CMC Crypto 200
1,394.54 +11.97 (+0.87%)
Gilead Sciences Inc (GIS.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 05:03PM CEST. Market open.
| Previous close | 62.44 |
| Open | 62.19 |
| Bid | 61.20 x 100000 |
| Ask | 61.23 x 100000 |
| Day's range | 61.00 - 62.96 |
| 52-week range | 61.00 - 80.26 |
| Volume | |
| Avg. volume | 150 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.